

Kimberly Van Deventer
5347 Kew Cliff Road
West Vancouver, British Columbia
V7W 1M3

EARLY WARNING NEWS RELEASE

Vancouver, British Columbia, July 4, 2017, Kimberly Van Deventer ("**Ms. Van Deventer**"), a director of PreveCeutical Medical Inc., formerly Carrara Exploration Inc. (the "**Issuer**"), makes the following announcement in accordance with National Instrument 62-103 *The Early Warning System and Related Take Over Bids* and National Instrument 62-104 *Take-Over Bids and Issuer Bids*.

Ms. Van Deventer advises that on June 30, 2017, she acquired ownership and control of 7,000,000 common shares in the capital of the Issuer, at a deemed issuance price of \$0.50 per share, pursuant to an amalgamation agreement dated March 21, 2017, whereby the Issuer acquired all of the issued and outstanding shares of 1050962 B.C. Ltd., formerly PreveCeutical Medical Inc. (the "**Transaction**"). The common shares of the Issuer (the "**PreveCeutical Shares**") are listed for trading on the Canadian Securities Exchange, however, the Transaction did not occur on a stock exchange or other market that represents a published market for securities.

Immediately before the completion of the Transaction, Ms. Van Deventer did not beneficially own or control any PreveCeutical Shares. As a result of the Transaction, Ms. Van Deventer beneficially owns and controls 7,000,000 PreveCeutical Shares, together with 250,000 common share stock options, representing approximately 14.29% (14.72% on a partially diluted basis) of the currently issued and outstanding PreveCeutical Shares.

Ms. Van Deventer acquired the PreveCeutical Shares for investment purposes. However, Ms. Van Deventer will review her holdings from time to time and may, in the future, increase or decrease her ownership or control over securities of the Issuer as circumstances dictate.

Upon the completion of the Transaction, the Issuer became a health and wellness company focused on utilizing nature and science for the benefit of health conscious consumers and that markets nutraceutical products to such consumers. The Issuer has one product for sale, the CELLB9™ which is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide, obtained from Caribbean blue scorpion venom. Management of the Issuer is currently working to research and develop other health and wellness products utilizing peptides contained in Caribbean blue scorpion venom and cannabinoids (the chemical constituents of marijuana).

An early warning report will be filed under the Issuer's profile on the SEDAR website at www.sedar.com. A copy of the early warning report can also be obtained from the contact below.

The Issuer's head office is located at Suite 2200, 1177 West Hastings Street, Vancouver, British Columbia, V6E 2K3.

For more information contact:

Kimberly Van Deventer
(604) 505-2204